Receptor CDCP1 is a potential target for personalized imaging and treatment of poor outcome HER2+, triple negative and metastatic ER+/HER2- breast cancers.
Gough M, Kwah KK, Khan T, Ghosh S, Sun B, Lee CY, Sokolowski KA, Tse BW, Wickramasuriya L, Ferguson K, Rogers R, Goh JB, Fletcher NL, Houston ZH, Thurecht KJ, Bray LJ, Liu C, Pyke C, Lim E, Snell CE, He Y, Hooper JD, Kryza T.
Gough M, et al. Among authors: khan t.
Clin Cancer Res. 2025 Jan 27. doi: 10.1158/1078-0432.CCR-24-2865. Online ahead of print.
Clin Cancer Res. 2025.
PMID: 39869307